No Shocker Here: Theravance Gets FDA "Complete Response" For Telavancin
This article was originally published in The Pink Sheet Daily
Executive Summary
Telavancin NDA for nosocomial pneumonia on hold as FDA asks for more mortality data while it assesses new requirements for HAP antibiotics.